Literature DB >> 8012062

Anticancer drug sensitivity profiles of new and established melanoma cell lines.

E S Marshall1, K M Holdaway, J H Shaw, G J Finlay, J H Matthews, B C Baguley.   

Abstract

Metastatic melanoma is notable for its resistance to chemotherapy, and methods for determining resistance in cultures would be advantageous. We investigated the chemosensitivities of seven newly derived low passage lines and eight established melanoma lines. A 96-well microculture system utilising [3H]-thymidine incorporation was used to determine IC50 values (50% inhibitory concentrations) for lomustine, mitomycin C, 4-hydroperoxycyclophosphamide, cisplatinum, 5-fluorouracil, vincristine, doxorubicin, etoposide, amsacrine and the amsacrine analogue CI-921. Cytokinetic parameters were determined using 5-bromodeoxyuridine and flow cytometry. The presence of "transport" and "atypical" multidrug resistance was investigated with an IC50 ratio method, using pairs of drugs with differing sensitivity to these multidrug resistance mechanisms. A wide range of chemosensitivity for each of the antitumor agents was observed, and a spectrum of activity was observed in each of the assays for multidrug resistance. Unexpectedly, a number of cell lines displayed coordinate sensitivity or resistance to cytotoxic agents with unrelated mechanisms of action. Resistance mechanisms apart from "transport" and "atypical" multidrug resistance may be required to account for the observed 40-fold range in overall chemosensitivity of the melanoma lines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8012062

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  11 in total

1.  Analysis of radiation-induced changes to human melanoma cultures using a mathematical model.

Authors:  B Basse; W R Joseph; E S Marshall; B C Baguley
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

2.  Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide.

Authors:  B C Baguley; L Zhuang; E Marshall
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  A mathematical model for analysis of the cell cycle in cell lines derived from human tumors.

Authors:  Britta Basse; Bruce C Baguley; Elaine S Marshall; Wayne R Joseph; Bruce van Brunt; Graeme Wake; David J N Wall
Journal:  J Math Biol       Date:  2003-05-15       Impact factor: 2.259

4.  Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Authors:  Liangli Zhao; Elaine S Marshall; Lloyd R Kelland; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2007-01-03       Impact factor: 3.651

5.  Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.

Authors:  K Henare; L Wang; L-C S Wang; L Thomsen; S Tijono; C-J J Chen; S Winkler; P R Dunbar; C Print; L-M Ching
Journal:  Br J Cancer       Date:  2012-03-13       Impact factor: 7.640

6.  Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.

Authors:  Melanie Sweetlove; Emma Wrightson; Sharada Kolekar; Gordon W Rewcastle; Bruce C Baguley; Peter R Shepherd; Stephen M F Jamieson
Journal:  Front Oncol       Date:  2015-06-16       Impact factor: 6.244

Review 7.  MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a "Genetic Switch" Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma.

Authors:  Michael R Eccles; Shujie He; Antonio Ahn; Lynn J Slobbe; Aaron R Jeffs; Han-Seung Yoon; Bruce C Baguley
Journal:  Front Oncol       Date:  2013-09-11       Impact factor: 6.244

8.  Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.

Authors:  Gordon W Rewcastle; Sharada Kolekar; Christina M Buchanan; Swarna A Gamage; Anna C Giddens; Kit Y Tsang; Jackie D Kendall; Ripudaman Singh; Woo-Jeong Lee; Greg C Smith; Weiping Han; David J Matthews; William A Denny; Peter R Shepherd; Stephen M F Jamieson
Journal:  Oncotarget       Date:  2017-07-18

9.  The role of the hippo pathway in melanocytes and melanoma.

Authors:  Ji Eun Kim; Graeme J Finlay; Bruce C Baguley
Journal:  Front Oncol       Date:  2013-05-16       Impact factor: 6.244

10.  Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations.

Authors:  Euphemia Y Leung; Marjan E Askarian-Amiri; Dean C Singleton; Carole Ferraro-Peyret; Wayne R Joseph; Graeme J Finlay; Reuben J Broom; Purvi M Kakadia; Stefan K Bohlander; Elaine Marshall; Bruce C Baguley
Journal:  Front Oncol       Date:  2018-10-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.